نتایج جستجو برای: tenofovir

تعداد نتایج: 4096  

Journal: :Journal of hepatology 2011
Stefan Mauss Florian Berger Natalie Filmann Dietrich Hueppe Julia Henke Petra Hegener Christoph Athmann Guenther Schmutz Eva Herrmann

BACKGROUND & AIMS Therapy of chronic hepatitis B with HBV-polymerase inhibitors, in particular tenofovir or adefovir, may affect renal function. To assess renal function more accurately in the normal range, we used the recently validated, Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) formula to calculate the estimated glomerular filtration rate (eGFR). METHODS Patient subgroups ...

Journal: :Drug metabolism and disposition: the biological fate of chemicals 2000
J Van Gelder S Deferme P Annaert L Naesens E De Clercq G Van den Mooter R Kinget P Augustijns

Previous studies have shown that strawberry extract increases the transepithelial transport of tenofovir disoproxil, an esterase-sensitive prodrug of the antiviral compound tenofovir (formerly PMPA), across Caco-2 monolayers. This increase in transport was at least partially due to inhibition of its intestinal metabolism. To further study the feasibility of this absorption enhancing strategy, t...

Journal: :Cost effectiveness and resource allocation : C/E 2015
Guvenc Kockaya Akin Kose Fatma Betul Yenilmez Oktay Ozdemir Ece Kucuksayrac

BACKGROUND All international guidelines suggested that Tenofovir and Entecavir are the primary drugs at the first line therapy for the treatment of chronic hepatitis B (CHB). However, in Turkey these medications reimbursed at the second line therapy according to the Healthcare Implementation Notification. The aim of this study is to compare the cost effectiveness of oral antiviral treatment str...

2011
Takeshi Nishijima Hirokazu Komatsu Hiroyuki Gatanaga Takahiro Aoki Koji Watanabe Ei Kinai Haruhito Honda Junko Tanuma Hirohisa Yazaki Kunihisa Tsukada Miwako Honda Katsuji Teruya Yoshimi Kikuchi Shinichi Oka

BACKGROUND Treatment with tenofovir is sometimes associated with renal dysfunction. Limited information is available on this side effect in patients with small body weight, although the use of tenofovir will spread rapidly in Asia and Africa, where patients are likely to be of smaller body weight. METHODS In a single-center cohort, Japanese patients with HIV infection who started tenofovir-co...

Journal: :Antimicrobial agents and chemotherapy 2005
J A H Droste C P W G M Verweij-van Wissen B P Kearney R Buffels P J Vanhorssen Y A Hekster D M Burger

Tenofovir disoproxil fumarate (tenofovir DF) was studied in combination with rifampin in 24 healthy subjects in a multiple-dose, open-label, single-group, two-period study. All subjects were given tenofovir DF at 300 mg once a day (QD) from days 1 to 10 (period 1). From days 11 to 20 the subjects received tenofovir DF at 300 mg combined with rifampin at 600 mg QD (period 2). The multiple-dose p...

Journal: :Antimicrobial agents and chemotherapy 2004
Rohan Hazra Frank M Balis Antonella N Tullio Ellen DeCarlo Carol J Worrell Seth M Steinberg John F Flaherty Kitty Yale Marianne Poblenz Brian P Kearney Lijie Zhong Dion F Coakley Stephane Blanche Jean Louis Bresson Judith A Zuckerman Steven L Zeichner

Tenofovir disoproxil fumarate (DF) is a potent nucleotide analog reverse transcriptase inhibitor approved for the treatment of human immunodeficiency virus (HIV)-infected adults. The single-dose and steady-state pharmacokinetics of tenofovir were evaluated following administration of tenofovir DF in treatment-experienced HIV-infected children requiring a change in antiretroviral therapy. Using ...

2014
Formijn J. van Hemert Ben Berkhout Hans L. Zaaijer

INTRODUCTION Resistance of the reverse transcriptase (RT) of hepatitis B virus (HBV) to the tenofovir nucleotide drug has not been observed since its introduction for treatment of hepatitis B virus (HBV) infection in 2008. In contrast, frequent viral breakthrough and resistance has been documented for adefovir. Our computational study addresses an inventory of the structural differences between...

2016
Tino Salome Ivan Kasamba Billy Nsubuga Mayanja Patrick Kazooba Jackson Were Pontiano Kaleebu Paula Munderi Billy N. Mayanja Judith Nalwadda Gladys Nakibuuka Harriet Namugenyi Patrick Kazooba Rosemary Lubega Annet Mugisha Apophia Tereka Apuuli Kalyebara Arthur Namara Diana Nakitto Deus Wangi Fred Nume George Ssemwanga Gertrude Nabulime Gladys Nassuna Gloria Lubega Ivan Namakoola Joseph Lutaakome Lillian Generous Lydia Matama Rosemary Massa Salome Tino William Nakahima Anne A. Kapaata Brian Magambo Chris Parry Frederick Lyagoba Jamirah Nazziwa Maria Nannyonjo Edward Muhigirwa Faith Wamalugu Florence Kabajuma Hope Grania Nakazibwe Jackson Were Joan Bwandinga Juliet Bukenya Member Zephyrian Kamushaaga Peter Hughes Peter Nkurunziza Priscilla Agatha Balungi Simon Mukasa Sureyah Nassimbwa Tobias Vudriko William Senyonga Willyfred Ochola Annet Nakimbugwe Catherine Nampewo Doreen Nambuba Erima Naphtali Grace Barigye Irene Nakamanya Ivan Kasamba Jonathan Levin Joseph Kahwa Joy Namutebi Matovu Lillian Namayirira Ruth Namulindwa Lubega Sandra Nabalayo Solomon Kaddu Paula Munderi

BACKGROUND WHO recommends using Tenofovir containing first line antiretroviral therapy (ART), however, Tenofovir has been reported to be associated with renal impairment and dysfunction. We compared renal function among individuals on Tenofovir and those on non-Tenofovir containing ART. METHODS In a cross-sectional study of HIV-Positive adults on ART, at enrolment into a prospective cohort to...

Journal: :Frontiers in Pharmacology 2023

Introduction : Sarcopenia is defined as a loss of muscle mass and strength. ATP homeostasis crucial during myogenesis. We determined how the purinergic system modulates myogenesis using dipyridamole (blocks adenosine taken up by cells) tenofovir (inhibits release) in myoblast cell line. Methods: C2C12 cells were differentiated presence/absence tenofovir/dipyridamole, with/without A2B selective ...

Journal: :Antimicrobial agents and chemotherapy 2013
Peter L Havens Jennifer J Kiser Charles B Stephensen Rohan Hazra Patricia M Flynn Craig M Wilson Brandy Rutledge James Bethel Cynthia G Pan Leslie R Woodhouse Marta D Van Loan Nancy Liu Jorge Lujan-Zilbermann Alyne Baker Bill G Kapogiannis Catherine M Gordon Kathleen Mulligan

Tenofovir disoproxil fumarate (TDF) causes bone, endocrine, and renal changes by an unknown mechanism(s). Data are limited on tenofovir pharmacokinetics and these effects. Using baseline data from a multicenter study of HIV-infected youth on stable treatment with regimens containing TDF (n = 118) or lacking TDF (n = 85), we measured cross-sectional associations of TDF use with markers of renal ...

نمودار تعداد نتایج جستجو در هر سال

با کلیک روی نمودار نتایج را به سال انتشار فیلتر کنید